Corneal Cross-Linking Procedure in Progressive Keratoconus Treatment

Arleta Waszczykowska*

Department of Ophthalmology and Vision Rehabilitation, Poland

Received: February 01, 2018; Published: February 12, 2018

*Corresponding author: Arleta Waszczykowska, Department of Ophthalmology and Vision Rehabilitation, Medical University of Lodz, Zeromskiego 113, 90-549 Lodz, Poland, Tel: 48 426396343; Email: arletawaszczykowska@interia.pl

Abstract

Keratoconus is a progressive eye disease, which discloses in adolescence and usually stabilizes in the fourth or fifth decade of life. The progressive thinning of corneal stroma in which the cornea has a conical shape leads to high irregular astigmatism and consequently to a significant visual acuity decrease. Any method to cure this disease has been developed to this day. Corneal collagen cross-linking (CXL) is the first treatment that halts the progression of keratoconus. Cross-linking conducted in the early stages of keratoconus allows to stop corneal changes during early grade, easier to optical correction. From the times of “Dresden Protocol” until now, multiple variations of the standard procedure technique have been introduced and consistent improvement is still being searched for. Not only does the study present the classical method of CXL, accelerated and transepithelial CXL modifications, but the latest research about their effectiveness as well.

Keywords: Corneal cross-linking; CXL; Accelerated cross-linking; High irradiance; Transepithelial cross-linking; Keratoconus

Introduction

A literature review

Cross-linking (X-linking, CXL) is a surgical procedure designed to strengthen the corneal structure and stop the progression of keratoconus. Cross-linking method was applied for the first time in Technical University in Dresden (Germany) in 1998 [1]. Efficacy and safety of the method was later confirmed in multiple clinical studies conducted worldwide [2,3]. Range of indications for CXL procedure is currently widened to include, e.g. treatment of post-operative corneal ectasia, bullous keratopathy, lattice corneal dystrophy, infectious corneal ulceration (Photo Activated Chromophore for Keratitis Cross-linking, PACK-CXL). The procedure is also sometimes combined with refractive surgery of the cornea (CXL-Phas) [4]. Also some attempts were made to apply CXL procedure as supplementary to orthokeratology, keratoplasty or for the treatment leaking cystic blebs after trabeculectomy [5,6]. The most recent reports indicate that scleral cross linking with riboflavin and ultraviolet-A radiation effectively prevents axial myopia in a rabbit model [7].

Standard CXL methodology involves removal of corneal epithelium (Epithelium-Off) to improve penetration of riboflavin (vitamin B2), as epithelium provides a natural diffusion barrier for it. Repeated applications (for approx. 30 minutes) of 0.1% riboflavin solution in 20% dextran enable high riboflavin concentration in the corneal stroma to be achieved. Appropriate saturation of the corneal stroma with riboflavin has been proven to multiply many times absorption of radiation by anterior corneal layers, which prevents penetration of UVA into deeper eye structures [2]. The cornea is exposed to ultraviolet radiation at wavelength of 365 nm (UVA) and power of 3mW/cm² for subsequent 30 minutes, with concomitant application of riboflavin (Figure 1).

Figure 1: Corneal UVA radiation exposure after 30-minute of riboflavin solution application.

Duration of the procedure is a drawback of CXL method. Standard procedure lasts 1 hour, which is burdensome for the patients and significantly limits number of procedures that may be performed. Moreover, epithelium removal requires relatively prolonged process of epithelium restoration and is frequently...
associated with eye pain and necessity of wearing protective contact lenses [1,8]. Numerous modifications of standard CXL technique were implement until now, some of them aimed at the protection of corneal epithelium, while others - with tendency to reduce the procedure duration.

**Various Aspect of CXL Methodology**

The procedure is performed in patients with progressive morphologic changes in the course of low-stage of keratoconus (stage 1, 2 or sometimes 3 according to Amsler-Krumeich’s classification). Progression of keratoconus is defined as fulfilling of at least one of the following criteria: increase in Kmax of 1 diopter (D) in 1 year, or a change in either myopia and/or astigmatism ≥3 D in 6 months, a mean central K-reading change ≥1.5 D observed in three consecutive topographies in 6 months, or a mean central corneal thickness decrease ≥5 % in three consecutive topographies in the previous 6 months [9]. Safety of the CXL procedure, apart from the UVA dose applied, also depends on the corneal thickness, which should not be lower than 400 μm. Such a corneal thickness is known to prevent successfully damage to endothelial cells during UV irradiation. Effect of the procedure has been shown to be limited to 200-350 μm of corneal thickness (Figure 2).

![Figure 2: Optical Coherence Tomography image showing demarcation line at 278μm, 24 months after accelerated CXL.](image)

However, it should be borne in mind that during CXL procedure corneal thickness is reduced, by 19% on the average, due to dehydration [10,11]. The process is also facilitated by thinning of corneal stroma following epithelium removal. Reduction of the corneal thickness during the CXL procedure is known to occur in two stages. During the first stage, involving a 30-minute period of riboflavin administration, corneal thinning may even amount to 15%. The patient is recommended to keep their eyes closed and open them only for the moment of the drop instillation. Such an approach allows changes detected in pachymetry to be reduced and may even result in insignificant improvement (approx. 1%) of corneal thickness [12]. The other and more intense stage of corneal thinning involves the UVA irradiation phase [10]. Relatively high rate of CXL procedure complications (7.6%) enforces rigorous qualification of patients to the procedure [5].

The following exclusion criteria for cross-linking procedure are mentioned:

a. Pre-operative keratometry results ≤ 58 D.

b. Age > 35 years. Risk of complications in young patients is 1.04%.

c. Corneal thickness following epithelial abrasion < 400 μm. Corneal thickness following lower than 400 μm significantly increases the risk of endothelial cells damage.

d. Visual acuity 20/25 or better.

There is a risk of lower acuity after the procedure. Lack of any effect of CXL procedure is noted in patients with high pre-operative keratometry results, as well as in patients with neurodermitis and pregnant women, likely due to hormonal disturbances [5]. Question of efficacy of CXL procedure is raised in numerous publications, while there is much less information concerning actual and possible complications. Possible complications following CXL procedure are presented in Table 1 [5,13-16]. It has been proven that CXL procedure is associated with keratocyte apoptosis, atrophy of nerve plexuses and oedema of anterior layers of corneal stroma. Average time for complete epithelial re-epithelisation is 5 days.

**Table 1: Complications after CXL procedure.**

<table>
<thead>
<tr>
<th>Complications after CXL procedure</th>
<th>Early</th>
<th>Late</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chronic pain</td>
<td></td>
<td>Sterile corneal infiltrates</td>
</tr>
<tr>
<td>Photophobia</td>
<td></td>
<td>Infectious keratitis (bacterial, viral, Acanthamoeba)</td>
</tr>
<tr>
<td>Fixed excessive corneal sensitivity to temperature changes</td>
<td></td>
<td>Delayed healing of the epithelium</td>
</tr>
<tr>
<td>Reduction of visual acuity</td>
<td></td>
<td>Recurrent keratitis</td>
</tr>
<tr>
<td>The “glare” phenomenon</td>
<td></td>
<td>Focal, transient or permanent corneal opacity</td>
</tr>
<tr>
<td>Corneal edema</td>
<td></td>
<td>Permanent scars in corneal stroma</td>
</tr>
<tr>
<td>Dense mild stromal opacity (Figure 3)</td>
<td></td>
<td>Corneal degeneration (the demarcation line within the area of corneal abrasion)</td>
</tr>
<tr>
<td>Oiliary hyperemia</td>
<td></td>
<td>Endothelopathy with corneal edema</td>
</tr>
<tr>
<td>Inflammatory cells in aqueous humor</td>
<td></td>
<td>Kerato-uveitis</td>
</tr>
</tbody>
</table>


Process of restoration of subepithelial nerve plexus starts approx. 1 month after the procedure, while keratocyte repopulation 3-6 months after CXL procedure. New collagen fibres rebuilt in these processes are thicker, more rigid and more resistant to extracellular matrix enzymes [5]. According to abundant literature, rate of the disease progression following standard CXL procedure amounts to 2.9-7.6% and depends on the stage of keratoconus [17]. Progression of the disease despite CXL procedure has been proven to occur more frequently in patients with baseline $K_{\text{max}}$ values above 58 D [17,18].

### Functional Results and Morphometric Parameters of Cornea Following the Standard CXL Procedure

The conclusions of majority of studies analysing outcome of standard CXL procedure indicate some improvement in visual acuity in keratoconus patients [5]. A significantly lower number of papers report lack of such effect [19-21]. CXL procedure is known to reduce both $K_{\text{max}}$ and $K_{\text{min}}$ values [22,23]. Such changes are usually noted during the first year after the procedure. However, it should be mentioned that there are cases of delayed change of $K_{\text{max}}$ value, occurring as late as between the 24th and 36th month of the follow-up [22-24]. Significant corneal flattening ($\Delta K_{\text{max}} > 1$ D) occurs in over 50% patients within one year after the procedure, while in 13% of them the change amounts to even $> 2$ D [25]. Some studies suggest that corneal flattening following CXL is correlated with the stage of disease progressions. Some authors noted more marked corneal flattening in more advanced keratoconus cases, with $K_{\text{max}}$ values within 54-58 D range [22,25]. Conversely, other authors reported more significant corneal flattening in initial stages of keratoconus, with $K_{\text{max}}$ values ≤ 53 D [26].

According to some studies, changes of corneal thickness are observed after CXL procedure. Independent analyses by Witting-Sliva et al. and Caprossi et al. indicated that there were no differences in corneal thickness as assessed by ultrasound pachymetry (USP) during 3-year follow-up; however, examinations performed by means of Orbscan apparatus revealed significant corneal thinning within first 3 month after the procedure [22]. Results of corneal thickness measurements performed by means of Orbscan apparatus, HRT, confocal pachymetry and OCT were equivocal [27]. Other authors demonstrated significant differences in corneal thickness after standard CXL procedure in examinations with Scheimpflug camera at various stages of follow-up Topraket et al. [28] and Greenstein et al. [29] reported reduction in corneal thickness in 6th and 12th month, respectively. Hashemi et al. noted significant corneal thinning in 1st month after standard CXL procedure. The authors also stress the fact that in subsequent check-ups corneal thickness increased gradually up to 6th month after the procedure, achieving values similar to baseline ones [19].

The general opinion is that corneal thickness changes after the CXL procedure results from the keratocyte restoration process that lasts approx. 6 months. Additionally, the rearrangement of the corneal lamellae, anatomic and structural changes of the collagen fibres and changes in corneal stroma (glycosaminoglycans) last approx. 2 years after the procedure [30]. Other authors explain the changes with the damage and subsequent restoration of nerve fibres, which may affect the corneal sensation and endothelial pump performance [31]. Corneal ischaemia, a tighter arrangement of collagen lamellae and changes in the arrangement of the restored corneal epithelium are listed among the other possible causes [10].

### Modifications of cross-linking procedure

Attempts to reduction the cross-linking procedure duration are based on shorter riboflavin administration time (e.g. with the use of iontophoresis) or on the application of higher UV doses (accelerated cross-linking, fast cross-linking, rapid cross-linking). Theoretical background for the modification of the method is based on the photochemical reciprocity law (Bunsen-Roscoe law), according to which rate of the photochemical and photobiological reaction is directly proportional to the total dose of radiation energy. It means in general, that similar effect of corneal cross-linking, similar to that achieved with the standard CXL method, may be achieved with various intensity and duration of UVA irradiation, provided that an identical total dose of energy is delivered [32,33].

Experimental trials have demonstrated that prolongation of exposure to light up to 60 minutes, and thus exceeding UVA energy dose above 5.4 J/cm², does not result in the outcome similar to this of standard method, while biomechanical strength of such cornea is similar to cornea not exposed to CXL irradiation procedure [34]. Moreover, exceeding the safe radiation dose, considered to be 5.4 J/cm² may significantly increase the risk of phototoxic intraocular complications [2,5]. Thus, modifications of cross-linking procedure consist in the proportional change of UVA irradiation duration and intensity, with a constant safe dose of total radiation dose energy. The majority of studies evaluating the efficacy and safety of modifications of alternative CXL methods involve experimental studies on the porcine cornea (Figure 3).

![Figure 3: Corneal haze after CXL procedure (blue arrow).](image-url)
literature. Schumacher et al. demonstrated the equal efficacy of the accelerated cross-linking and standard CXL procedure on the porcine cornea, with UVA irradiation at a power of 10 mW/cm² for 9 minutes [33]. Wernli et al. [35] noted an increased corneal stiffness in line with the increase of UVA intensity to 45 mW/cm² and a decrease in the exposure time to 2 minutes. On the other hand, with combination of higher UVA intensity (above 50 mW/cm²) and shorter irradiation duration, no significant changes of corneal stiffness was demonstrated. Interestingly, the most recent reports stress the fact that higher UVA intensity and shorter irradiation time result in poorer CXL outcome [36]. The effect is explained by increased oxygen consumption and, consequently, lower efficiency of photochemical reactions during fats CXL procedure [37]. This is supported by results indicating the complete lack of effects of the CXL performed in anaerobic conditions [38].

Postoperative results of accelerated CXL procedure are equivocal. There are literature reports on significant reduction of Kmax value and improvement in visual acuity, as well as papers indicating no significant changes in keratometry results [39-40]. Reduced keratocyte destruction would be a strong argument supporting the development of alternative CXL methods [39]. However, such a claim was not confirmed by results of the corneal confocal microscopy in patients following the fast CXL procedure (in modification involving 30 mW/cm² UVA for 3 minutes). The results revealed more intense morphological changes than following a standard CXL procedure, as well as increased keratocytes apoptosis, tissue hyper reflectivity, and more numerous and darker stromal defects [41].

Another CXL modification, enabling protection of corneal epithelial, is “Epithelium-On” method.1 The following methods are applied to increase vitamin B2 penetration through intact corneal epithelium: viscous riboflavin solution, the use of a ring limiting outflow of the solution, modification of its osmolarity or riboflavin concentration and/or the use of iontophoresis. Better penetration may be also achieved thanks to increased epithelial permeability due to loosening of intercellular junctions following administration of benzalkonium chloride (BAC), ethylenediaminetetraacetic acid (EDTA) or NC-1059 peptide, or thanks to formation of pockets for penetration of riboflavin solution. J Cataract Refract Surg 39: 1179-1183.

To date, numerous critical data concerning this method were published, indicating poorer control of keratoconus progression, as compared to standard CXL method [42]. It has been suggested to result from reduced penetration of riboflavin through the layers of epithelium and Bowman’s membrane, as well as uneven distribution of riboflavin within corneal stroma. Moreover, presence of dextran in riboflavin solution has been proven to additionally reduce penetration of riboflavin through epithelium [43]. Also epithelial cells reduce penetration of UVA by approx. 20-30%.

Some reports stress that total dose of UVA energy applied in Epithelium-On should be 7.2 J/cm² to be equivalent to standard CXL procedure. The claim is supported by studies by E. Yuksel et al. [44,45], that involved over a 1 year follow-up of keratoconus progression inhibition after Epithelium-On CXL procedure involving the use of suggested dextran-free riboflavin dose and UVA power. Despite multiple modifications and attempts to combine CXL methods with refractive surgery of cornea and lens, standard CXL is currently the most common method of keratoconus therapy. However, problems and complications inherent to the procedure methodology are still a strong argument for seeking alternative methods. We wish to confirm that there are no conflicts of interest associated with this publication and there has been no financial support for this work that could influence its outcome.

References


